Community protocol
Third-partyPE-22-28 10mg
- 01Reconstitution solution
- 3 mL
- 02Dose
- 0.15 mg
- 03Syringe units
- 5 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 3 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 2
PE-22-28
A short peptide derived from spadin, investigated as a fast-acting antidepressant through a mechanism unrelated to serotonin reuptake. Rodent data only.
Overview
Standard antidepressants take weeks to work. Researchers noticed that mice lacking a potassium channel called TREK-1 behave as if they are already on antidepressants, and that blocking that channel might produce the same effect quickly. Spadin is a natural peptide that blocks TREK-1; PE-22-28 is a shortened, more potent version of it. In rodents it produced antidepressant-like effects within days rather than weeks.
A seven-residue fragment derived from spadin, itself a propeptide generated during sortilin/neurotensin receptor-3 maturation. Blocks the two-pore-domain potassium channel TREK-1, which is negatively coupled to serotonergic tone; TREK-1 knockout mice display a depression-resistant phenotype. Rodent administration produces antidepressant-like effects in forced swim, novelty-suppressed feeding and chronic corticosterone models within 4 days, alongside increased hippocampal neurogenesis and synaptogenesis markers. Human pharmacology is entirely unstudied.
Research areas
DepressionTREK-1 channel biologyNeurogenesis
Community-specified data
Community dosage information
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Intranasal PE-22-28 in mouse models of depression with behavioural endpoints over 4 days | Djillani et al., Frontiers in Pharmacology 2017 |
Trial status
Preclinical only.
Reported safety signals
- No human safety data of any kind.
- TREK-1 is expressed in cardiac and vascular tissue as well as brain, so systemic channel blockade is not CNS-selective.
- Sold through unregulated channels with no verified identity.
Common questions
Would this work faster than an SSRI?
In mice, the antidepressant-like effect appeared within about four days rather than the two to three weeks typical of SSRIs. Whether that translates to humans is completely untested — no person has taken it in a study.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →